Aldosteronism

Aldosteronism, also termed hyperaldosteronism, is an endocrine disorder characterized by excessive secretion of the mineralocorticoid hormone aldosterone It primarily impacts the cardiovascular and renal systems and is categorized into primary forms, caused by autonomous adrenal pathology such as bilateral adrenal hyperplasia or aldosterone-producing adenomas, and secondary forms driven by extra-adrenal activation of the renin-angiotensin-aldosterone system

Aldosteronism, also termed hyperaldosteronism, is an endocrine disorder characterized by excessive secretion of the mineralocorticoid hormone aldosterone It primarily impacts the cardiovascular and renal systems and is categorized into primary forms, caused by autonomous adrenal pathology such as bilateral adrenal hyperplasia or aldosterone-producing adenomas, and secondary forms driven by extra-adrenal activation of the renin-angiotensin-aldosterone system Pathophysiologically, sustained hypera...

It primarily impacts the cardiovascular and renal systems and is categorized into primary forms, caused by autonomous adrenal pathology such as bilateral adrenal hyperplasia or aldosterone-producing adenomas, and secondary forms driven by extra-adrenal activation of the renin-angiotensin-aldosterone system

Pathophysiologically, sustained hyperaldosteronism promotes excessive renal sodium reabsorption and potassium excretion, producing plasma volume expansion, systemic hypertension—frequently resistant to conventional antihypertensive therapies—and variable degrees of hypokalemia and metabolic alkalosis

Pathophysiologically, sustained hyperaldosteronism promotes excessive renal sodium reabsorption and potassium excretion, producing plasma volume expansion, systemic hypertension—frequently resistant to conventional antihypertensive therapies—and variable degrees of hypokalemia and metabolic alkalosis

Left unmanaged, the chronic mineralocorticoid excess substantially increases the risk of target-organ damage, including adverse cardiovascular events, chronic kidney disease, and stroke

Left unmanaged, the chronic mineralocorticoid excess substantially increases the risk of target-organ damage, including adverse cardiovascular events, chronic kidney disease, and stroke

Left unmanaged, the chronic mineralocorticoid excess substantially increases the risk of target-organ damage, including adverse cardiovascular events, chronic kidney disease, and stroke